| Literature DB >> 20162629 |
Barbara Wiśniowiecka-Kowalnik1, Monika Nesteruk, Sarika U Peters, Zhilian Xia, M Lance Cooper, Sarah Savage, R Stephen Amato, Patricia Bader, Marsha F Browning, Christa L Haun, Andrew Walter Duda, Sau Wai Cheung, Paweł Stankiewicz.
Abstract
NRXN1 is highly expressed in brain and has been shown recently to be associated with ASD, schizophrenia, cognitive and behavioral abnormalities, and alcohol and nicotine dependence. We present three families, in whom we identified intragenic rearrangements within NRXN1 using a clinical targeted oligonucleotide array CGH. An approximately 380 kb deletion was identified in a woman with Asperger syndrome, anxiety, and depression and in all four of her children affected with autism, anxiety, developmental delay, and speech delay but not in an unaffected child. An approximately 180 kb tandem duplication was found in a patient with autistic disorder and cognitive delays, and in his mother and younger brother who have speech delay. An approximately 330 kb tandem duplication was identified in a patient with autistic features. As predicted by conceptual translation, all three genomic rearrangements led to the premature truncation of NRXN1. Our data support previous observations that NRXN1 may be pathogenic in a wide variety of psychiatric diseases, including autism spectrum disorder, global developmental delay, anxiety, and depression. (c) 2010 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20162629 DOI: 10.1002/ajmg.b.31064
Source DB: PubMed Journal: Am J Med Genet B Neuropsychiatr Genet ISSN: 1552-4841 Impact factor: 3.568